Dr. Adam T. Gerstenblith, MD
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
- Medicare participating
At a glance
- Medical school
- Johns Hopkins University School of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 1,566
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: Johns Hopkins University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
MD license D0075032 · PA license MD442919 -
Internal Medicine Physician
MD license 21124
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Meritus Medical Center Hagerstown, MD
Medical groups
- Robert E PArnes MD LLC (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,566
- Services billed
- 88,251
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 71,160 | 333 |
| Imaging of retina | 3,048 | 1,265 |
| Established patient complete exam of visual system | 2,880 | 1,234 |
| Injection of drug into eye | 2,166 | 479 |
| Injection, aflibercept, 1 mg | 1,642 | 310 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 1,085 | 37 |
| New patient complete exam of visual system | 345 | 345 |
| Photography of the retina | 127 | 123 |
| Unclassified drugs | 109 | 45 |
| Established patient problem focused exam of visual system | 83 | 67 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Hagerstown, MD | 82 |
| Polymyxin B Sul-Trimethoprim (polymyxin b sulf/trimethoprim) | 58 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Hagerstown, MD | 33 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Hagerstown, MD | 31 |
| Difluprednate | 15 |
| Bromfenac Sodium | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $31.74 in total to this clinician.
| Ani Pharmaceuticals, Inc. | $31.74 |
|---|
| Food and Beverage | $31.74 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 8 companies. The companies reported $3,465,602 in research payments for these studies, mostly to the institutions running them.
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914 - Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. - A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular dege…
Boehringer Ingelheim Pharmaceuticals, Inc. - A phase 2, multicenter, randomized, double-masked, parallel-group study to assess the efficacy and safety of KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with diabetic macular edema
Kyowa Kirin, Inc. - Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503 - An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Apellis Pharmaceuticals, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Bayer HealthCare Pharmaceuticals Inc. - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-R…
Apellis Pharmaceuticals, Inc. - Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.